How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million. However, the company made significant strides in drug discovery and received FDA clearance for a new trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results